These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1034 related items for PubMed ID: 28498639

  • 1. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL, Sneige N, Gong Y, Bevers TB.
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [Abstract] [Full Text] [Related]

  • 2. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
    Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LA, Myers O, Cuzick J, Wentzensen N, Kinney W, Castle PE, Wheeler CM, New Mexico HPV Pap Registry Steering Committee.
    Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
    [Abstract] [Full Text] [Related]

  • 3. Age-specific 3-year cumulative risk of cervical cancer and high-grade dysplasia on biopsy in 9434 women who underwent HPV cytology cotesting.
    Ge Y, Christensen PA, Luna E, Armylagos D, Xu J, Hsu JW, Zhou H, Schwartz MR, Mody DR.
    Cancer Cytopathol; 2019 Dec; 127(12):757-764. PubMed ID: 31589379
    [Abstract] [Full Text] [Related]

  • 4. Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions.
    Zhou H, Mody RR, Luna E, Armylagos D, Xu J, Schwartz MR, Mody DR, Ge Y.
    Cancer Cytopathol; 2016 May; 124(5):317-23. PubMed ID: 26774025
    [Abstract] [Full Text] [Related]

  • 5. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
    Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
    [Abstract] [Full Text] [Related]

  • 6. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [Abstract] [Full Text] [Related]

  • 7. Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.
    Ryu KJ, Lee S, Min KJ, Kim JW, Hong JH, Song JY, Lee JK, Lee NW.
    Oncologist; 2015 Jun; 20(6):635-9. PubMed ID: 25964305
    [Abstract] [Full Text] [Related]

  • 8. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [Abstract] [Full Text] [Related]

  • 9. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.
    Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S56-63. PubMed ID: 23519306
    [Abstract] [Full Text] [Related]

  • 10. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A, Hebette G, Fischer M, Arbyn M, Weyers S, Vielh P, Schmitt F, Mossong J.
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [Abstract] [Full Text] [Related]

  • 11. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M, Solomon D, Wacholder S, Schiffman M, Castle P.
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [Abstract] [Full Text] [Related]

  • 12. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.
    Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S43-9. PubMed ID: 23519304
    [Abstract] [Full Text] [Related]

  • 13. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D, Zhang H, Li J, Austin M, Wang T, Pradhan D, Zhao C.
    J Am Soc Cytopathol; 2020 Apr; 9(6):550-555. PubMed ID: 32475726
    [Abstract] [Full Text] [Related]

  • 14. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
    Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
    [Abstract] [Full Text] [Related]

  • 15. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H, Varma KR, Han M, Matsko J, Zhao C.
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [Abstract] [Full Text] [Related]

  • 16. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection.
    Keller MJ, Burk RD, Xie X, Anastos K, Massad LS, Minkoff H, Xue X, D'Souza G, Watts DH, Levine AM, Castle PE, Colie C, Palefsky JM, Strickler HD.
    JAMA; 2012 Jul 25; 308(4):362-9. PubMed ID: 22820789
    [Abstract] [Full Text] [Related]

  • 17. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M, Wright TC, Stoler MH, Ranger-Moore J, Rehm S, Aslam S, Fang Q, Volkir P, Ridder R.
    Am J Obstet Gynecol; 2021 Sep 25; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [Abstract] [Full Text] [Related]

  • 18. Molecular Pap smear: HPV genotype and DNA methylation of ADCY8, CDH8, and ZNF582 as an integrated biomarker for high-grade cervical cytology.
    Shen-Gunther J, Wang CM, Poage GM, Lin CL, Perez L, Banks NA, Huang TH.
    Clin Epigenetics; 2016 Sep 25; 8(1):96. PubMed ID: 27651839
    [Abstract] [Full Text] [Related]

  • 19. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.
    Cancer Cytopathol; 2014 Nov 25; 122(11):842-50. PubMed ID: 25045058
    [Abstract] [Full Text] [Related]

  • 20. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.
    J Natl Cancer Inst; 2003 Jan 01; 95(1):46-52. PubMed ID: 12509400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.